Results of two separate phase 3 studies involving darafenacin hydrobromide (Enablex®, Novartis), an M₃ selective receptor antagonist being developed for the treatment of overactive bladder, reduced the frequency of weekly incontinence episodes (up to 77%) compared with placebo. It also decreased the number of weekly nocturnal awakenings caused by overactive bladder by 23%, versus 3.6% with placebo.
cialis canadian pharmacy

Related Posts:

• Trospium for Overactive Bladder
• Darifenacin Relieves Overactive Bladder